This HTML5 document contains 57 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n6http://linked.opendata.cz/resource/mesh/concept/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01218/identifier/wikipedia/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01218/identifier/pharmgkb/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01218/identifier/kegg-compound/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01218/identifier/bindingdb/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01218/identifier/pubchem-compound/
n12http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n23http://linked.opendata.cz/resource/drugbank/drug/DB01218/identifier/pubchem-substance/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01218/identifier/drugbank/
n21http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n10http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01218/identifier/chemspider/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01218
rdf:type
n3:Drug
n3:description
Halofantrine is a drug used to treat malaria. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferentially block open and inactivated HERG channels leading to some degree of cardiotoxicity.
n3:group
approved
n3:halfLife
6-10 days
n3:indication
For treatment of Severe malaria
owl:sameAs
n12:DB01218 n21:DB01218
dcterms:title
Halofantrine
adms:identifier
n15:50096846 n16:PA449839 n17:Halofantrine n18:C07634 n19:34303 n20:DB01218 n22:37393 n23:46506753
n3:mechanismOfAction
The mechanism of action of Halofantrine may be similar to that of chloroquine, quinine, and mefloquine; by forming toxic complexes with ferritoporphyrin IX that damage the membrane of the parasite.
n3:synonym
Halfan Halofantrina Halofantrine Halofantrinum
n3:toxicity
Side effects incldue coughing noisy, rattling, troubled breathing, loss of appetite, aches and pain in joints, indigestion,and skin itching or rash.
n3:foodInteraction
Take on an empty stomach, bioavailability is 6 times higher when drug is taken with high fat meals. Risks of cardiac toxicity are then increased.
n3:proteinBinding
60-70%;
n5:hasConcept
n6:M0081385
foaf:page
n10:halofantrine.html
n3:IUPAC-Name
n4:271B5855-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B585B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B585A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5857-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5858-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5859-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5853-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B586B-363D-11E5-9242-09173F13E4C5 n4:271B5851-363D-11E5-9242-09173F13E4C5 n4:271B5854-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5852-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n8:P01BX01
n3:H-Bond-Acceptor-Count
n4:271B5861-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5862-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B585C-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B585D-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B585F-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B585E-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5860-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Plasmodium
n3:casRegistryNumber
69756-53-2
n3:category
n3:Bioavailability
n4:271B5867-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5869-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B586A-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5866-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5865-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5868-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5856-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5863-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5864-363D-11E5-9242-09173F13E4C5